Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.43 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13503791 | 0.98 | ALDH1A1 (0.64) | ALDH1A1TSHRHSD11B1SMN1; SMN2LMNA | |
| SCHEMBL26227986 | 0.98 | ALDH1A1 (0.64) | ALDH1A1TSHRHSD11B1SMN1; SMN2LMNA | |
| SCHEMBL23153667 | 0.96 | ALDH1A1 (0.55) | ALDH1A1TSHRHSD11B1SMN1; SMN2LMNA | |
| SCHEMBL22875296 | 0.94 | ALDH1A1 (0.53) | ALDH1A1TSHRHSD11B1SMN1; SMN2LMNA | |
| SCHEMBL10119952 | 0.92 | HPGD (0.54) | ALDH1A1TSHRHSD11B1SMN1; SMN2LMNA | |
| SCHEMBL26494226 | 0.90 | HPGD (0.52) | ALDH1A1TSHRHSD11B1SMN1; SMN2LMNA | |
| SCHEMBL22540410 | 0.89 | HPGD (0.57) | ALDH1A1TSHRHSD11B1SMN1; SMN2LMNA | |
| SCHEMBL26046070 | 0.89 | ALDH1A1 (0.52) | ALDH1A1TSHRHSD11B1SMN1; SMN2LMNA | |
| SCHEMBL26228688 | 0.86 | HSD11B1 (0.48) | ALDH1A1TSHRHSD11B1SMN1; SMN2LMNA | |
| SCHEMBL14018490 | 0.85 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD11B1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023154124-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023125737-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2019-05-16 | — | — | US | disclosed |
| EP-3428160-A1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3027603-B1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2016-02-18 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | ALDH1A1 576/4885TSHR 1220/4885HSD11B1 52/4885 |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | ALDH1A1 576/4885TSHR 1220/4885HSD11B1 52/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | ALDH1A1 3363/4885TSHR 4155/4885HSD11B1 2624/4885 |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | ALDH1A1 576/4885TSHR 1220/4885HSD11B1 52/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | ALDH1A1 4009/4885TSHR 3587/4885HSD11B1 3349/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | ALDH1A1 1168/4885TSHR 1082/4885HSD11B1 291/4885 |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | ALDH1A1 576/4885TSHR 1220/4885HSD11B1 52/4885 |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | ALDH1A1 576/4885TSHR 1220/4885HSD11B1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.